Switch to under-the-skin ocrelizumab for multiple sclerosis
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial tests a new way of taking Ocrelizumab as a shot under the skin, for people with MS who are already on a similar treatment and want to switch. The goal is to see if switching is safe and works well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of relapsing MS or primary progressive MS (McDonald 2017 criteria).
- You are currently on an approved anti-CD20 therapy (Ocrevus, Kesimpta, or Briumvi) and your reason for switching is NOT that the drug stopped working or caused serious side effects like severe allergic reactions or frequent infections.
- Your disability level is mild to moderate (EDSS score between 0 and 6.5).
- You can have MRI scans and have no active or chronic infections (like HIV, tuberculosis, or hepatitis).
- You have not had a history of PML (a rare brain infection) or prior treatment with certain MS drugs (like cladribine, alemtuzumab, or mitoxantrone).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study will follow people with multiple sclerosis (MS) who are starting or restarting a treatment called Ocrevus (ocrelizumab). The goal is to understand how well it works in real life over 12 months. Participants will receive Ocrevus as part of their usual care and complete surveys about their experience.
This trial tests a biosimilar drug that acts like Ocrevus to treat multiple sclerosis. It aims to help manage disease activity and slow progression, and may be an option if you have relapsing or progressive MS.
This Phase 3 trial compares two similar immune therapies—rituximab and ocrelizumab—to see if rituximab works about as well for relapsing multiple sclerosis. It may help you and researchers understand which option is equally effective and safe for preventing relapses and disease activity.
This trial compares rituximab and ocrelizumab in people with relapsing-remitting multiple sclerosis (MS) to see which medicine better controls MS activity. It may help reduce future relapses and new MRI lesions.
This study looks at giving ocrelizumab treatments at home instead of in a clinic for people with MS. It’s meant to see if this approach is practical and acceptable while you keep receiving a medicine your MS doctor thinks you should continue.
This study looks at combining ocrelizumab (an MS treatment) with GLP-1 agonists (like Ozempic, used for weight management) in people with MS. It aims to see if the combination is safe and beneficial.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.